Prosecution Insights
Last updated: July 17, 2026
Application No. 18/845,962

HEXAGONAL BORON NITRIDE POWDER FOR COSMETIC USE AND COSMETIC

Non-Final OA §102§103
Filed
Sep 11, 2024
Priority
Mar 25, 2022 — JP 2022-049890 +1 more
Examiner
NGUYEN, NGOC-ANH THI
Art Unit
Tech Center
Assignee
JFE Mineral & Alloy Co. Ltd.
OA Round
1 (Non-Final)
32%
Grant Probability
At Risk
1-2
OA Rounds
1y 7m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants only 32% of cases
32%
Career Allowance Rate
19 granted / 59 resolved
-27.8% vs TC avg
Strong +46% interview lift
Without
With
+45.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
37 currently pending
Career history
107
Total Applications
across all art units

Statute-Specific Performance

§103
82.3%
+42.3% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
0.3%
-39.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 59 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The submitted information disclosure statements (IDS) were filed on 09/11/2024, 05/16/2025, 07/11/2025, 11/12/2025 and 02/03/2026. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 and 3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Matsui et al. (WO 2019172440 A1). Claim 1, Matsui et al. teach a boron nitride powder that comprises primary particles and/or aggregated primary particles, has an average particle diameter of 2.5-7.0 µm. (Abs). Hexagonal boron nitride has a layered structure similar to graphite. (pg. 2nd. 1st par.). The primary particles of hexagonal boron nitride are so-called “scale-shaped” particles. The aspect ratio of the primary particles of hexagonal boron nitride is preferably 8 to 23. (pg. 5, 3rd. par.). Since ratio is major axis length to thickness, then thickness = diameter/ratio, with diameter of 2.5-7.0 µm and the aspect ratio of the primary particles of hexagonal boron nitride is preferably 8 to 23, then thickness of the primary particles of hexagonal boron nitride is in the range of 0.11-0.88 µm. A hexagonal boron nitride powder having excellent tactile sensation can be obtained by adjusting the content of primary particles or aggregated particles of 36 µm or more contained in the powder to 10.0% by volume or less. The content of primary particles or aggregated particles of 36 µm or more contained in the hexagonal boron nitride powder is 10.0% by volume or less. (pg. 4, 2nd par.). The aggregated particles are secondary particles. With regard to claim 3, Matsui et al. teach boron nitride powder, a method for producing boron nitride powder, and a cosmetic containing boron nitride powder. (pg. 1, 2nd par.). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or non-obviousness. Claims 1, 2 and 4 are rejected under 35 U.S.C. 103 as being unpatentable over Matsui et al. (WO 2019172440 A1) in view of Ikeda et al. (JP 2019206455 A). claim 2, The teachings of Matsui et al. are described in claim 1 above. Matsui et al. teach the hexagonal boron nitride powder for cosmetic use according to Claim 1, but Matsui et al. do not teach wherein an oxygen concentration is 1.0 mass% or less. Ikeda et al. teach hexagonal boron nitride powder, (Abs), which is a raw material for processed boron nitride products to be used for applications such as cosmetics. (pg. 10, 3rd par.). The hexagonal boron nitride particles generally include primary particles made of thin scaly particles derived from a crystal structure. The boron nitride particles are easily oriented in the thickness direction in the thermally conductive insulating sheet. The hexagonal boron nitride particles have a hexagonal plane, and is generally hexagonal boron nitride particles are scaly. The hexagonal boron nitride powder having a small amount of the functional group has a low functional group amount, and thus has a poor affinity with the resin. When the resin composition is used, a thermal resistance is generated at the interface between the hexagonal boron nitride and the resin, There is a tendency that heat is not easily transmitted. As described above, when hexagonal boron nitride powder is used as an inorganic filler for resin filling, the lack of scale-like particle shape and surface functional groups becomes a barrier, and the above-described problem occurs. (pg. 2nd, 4th-6th par.). Hexagonal boron nitride particles can be layered. (pg. 8, 2nd last par.). The hexagonal boron nitride particles having an aspect ratio (major axis length to thickness ratio) of 4 to 12, and the aspect ratio is higher than that of conventional flaky hexagonal boron nitride particles. It is characterized by a small thick plate-like particle, and therefore a large proportion of the end face with respect to the plane. (pg. 5, 2nd last par.). Generally, the average particle size is preferably about 0.1 to 150 µm.(pg. 5, 2nd par.). Ikeda et al. teach the hexagonal boron nitride powder of the present invention preferably has an oxygen concentration of 0.3% by mass or less. (pg. 4, 3rd last par.). It would have been obvious for one of ordinary skill in the art before the effective filing date of the invention to have a boron nitride powder that comprises primary particles and/or aggregated primary particles, has an average particle diameter of 2.5-7.0 µm, wherein hexagonal boron nitride has a layered structure, the primary particles of hexagonal boron nitride are so-called “scale-shaped” particles. The aspect ratio of the primary particles of hexagonal boron nitride is preferably 8 to 23, and thickness of the primary particles of hexagonal boron nitride is in the range of 0.11-0.88 µm, and less than 10% aggregated particles or secondary particles, taught by Matsui et al., and the particles having less than 0.3% oxygen, taught by Ikeda et al. since they have proven it would be feasible to do so. With regard to claim 4, Matsui et al. teach boron nitride powder, a method for producing boron nitride powder, and a cosmetic containing boron nitride powder. (pg. 1, 2nd par.). Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NGOC-ANH THI NGUYEN whose telephone number is (571)270-0867. The examiner can normally be reached Monday - Friday 8:00 am. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NGOC-ANH THI NGUYEN/Examiner, Art Unit 1615 /Robert A Wax/Supervisory Patent Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Sep 11, 2024
Application Filed
Jun 04, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12667538
VILAZODONE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 0m to grant Granted Jun 30, 2026
Patent 12662673
LIPOPROTEIN-MIMICKING SOLID LIPID NANOPARTICLES FOR DRUG DELIVERY AND USES THEREOF
3y 4m to grant Granted Jun 23, 2026
Patent 12653184
SUSTAINED-RELEASE PHEROMONE PREPARATION
3y 6m to grant Granted Jun 16, 2026
Patent 12628858
THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS
4y 8m to grant Granted May 19, 2026
Patent 12629381
PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS
4y 3m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
32%
Grant Probability
78%
With Interview (+45.7%)
3y 5m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 59 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month